IGALMI - (EQ 0.12MG BASE,EQ 0.18MG BASE ; Film)

Generic Name	DEXMEDETOMIDINE	**Innovator**	Bioxcel
Dosage	EQ 0.12MG BASE,EQ 0.18MG BASE ; Film	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	IGALMI is an alpha2-adrenergic receptor agonist indicated in adults for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.